25.—(1) A product which is, or which contains, a substance listed in Annex II or Annex III to Council Directive 96/22 complies with the requirements of this regulation if—
(a)a marketing authorisation has been issued in relation to it;
(b)in the case of a product which is, or which contains, a beta-agonist, it has a withdrawal period of less than 28 days after the end of treatment; and
(c)in the case of a product which is, or which contains, a hormonal substance, it is not a product which falls within paragraph (2).
(2) A product falls within this paragraph if it—
(a)acts as a deposit;
(b)has a withdrawal period of more than 15 days after the end of treatment; or
(c)was authorised before 1st January 1995, has no known conditions of use and for which no reagents or equipment exists for use in the analytical techniques for detecting the presence of residues in excess of the prescribed limits.